Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673232 | 0.84 | HTR2A (0.35) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL476703 | 0.83 | CCR2 (0.35) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL20504942 | 0.79 | HTR2A (0.36) | ALDH1A1HTR2AHTR2C | |
| SCHEMBL476619 | 0.75 | ALDH1A1 (0.39) | MEN1ALDH1A1KMT2A | |
| SCHEMBL476691 | 0.74 | MCL1 (0.33) | HTR2AHTR2C | |
| SCHEMBL476675 | 0.72 | LMNA (0.34) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL22434876 | 0.71 | SIRT2 (0.37) | KDM4EMEN1KMT2AHTR2AHTR2C | |
| SCHEMBL20505256 | 0.67 | CYP1A2 (0.34) | ALDH1A1 | |
| SCHEMBL5672286 | 0.66 | CCR2 (0.37) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL2479489 | 0.61 | KDM4E (0.44) | KDM4EMEN1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951225-B1 | 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-7741363-B2 | 3-Acylindole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-06 | — | — | US | disclosed |
| EP-1951225-A2 | 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF | sanofi-aventis (FR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057571-A2 | 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | F12, ECI1, NQO2 | KDM4E 1501/4885MEN1 1241/4885ALDH1A1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.